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Abstract
Objective: Current United States immunization recommendations for adolescents include vaccines against
tetanus, diphtheria and pertussis (Tdap), human papillomavirus (HPV), and Neisseria meningitidis serogroups A, C,
W-135, and Y. In this Phase IV study, we primarily investigated the impact of concomitant administration of a
quadrivalent meningococcal CRM197-conjugate vaccine (MenACWY-CRM) with Tdap and HPV vaccines, in terms of
immunogenicity to Tdap antigens and overall reactogenicity.
Methods: A total of 801 healthy adolescents aged 10-18 years were randomized to one of two groups to receive
either MenACWY-CRM or a placebo, co-administered with Tdap and a quadrivalent HPV vaccine (HPV4). Antibody
responses to the Tdap antigens, as well as to meningococcal serogroups A, C, W-135, and Y, were assessed at one
month post-vaccination. Safety and adverse events were monitored throughout the study.
Results: One month post-vaccination, 95% and 99% of subjects in the MenACWY-CRM group had
seroprotective antibody levels (≥1.0 IU/mL) against the diphtheria and tetanus toxoids, respectively, compared with
82% and 98% in the placebo group. Ratios of geometric mean concentrations of antibodies against pertussis
antigens pertussis toxin, filamentous hemagglutinin and pertactin for the MenACWY-CRM group versus placebo
were 1.01, 0.84, and 0.82, respectively. Predetermined non-inferiority criteria for immunological responses against
all Tdap antigens were met. Co-administration of a single dose of MenACWY-CRM was well tolerated and elicited
robust antibody responses against the four meningococcal serogroups, with 77%, 84%, 95% and 86% of subjects
having seroprotective human complement serum bactericidal activity (titers ≥8) against serogroups A, C, W-135, and
Y, respectively, one month post-vaccination.
Conclusions: Collectively, these results demonstrate that the MenACWY-CRM, Tdap and HPV4 vaccines can
be administered at the same visit without compromising Tdap immune responses or increasing reactogenicity. [The
study is registered with ClinicalTrials.gov, number NCT01424644].
Keywords: Meningococcal; Conjugate vaccine; Adolescents; Tdap;
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Introduction
Infection by Neisseria meningitidis can rapidly lead to invasive
meningococcal disease (IMD), resulting in death in 8-14% of cases,
despite timely antibiotic treatment and supportive care [1]. Among
those individuals who survive IMD, 11-19% suffer devastating long-
term sequelae, including amputations and neurological impairments.
The incidence of IMD in industrialized nations is low, with estimates
of 0.53 cases per 100,000 population in the United States [2].
Cases often occur sporadically, but can also occur in small clusters,
with the latter becoming more common in recent years [3]. In other
parts of the world, such as in Africa, IMD is associated with large
epidemics, with an annual incidence greater than 1,000 cases per
100,000 population [3]. Most cases of IMD are caused by one of five
pathogenic serogroups, A, B, C, W-135 or Y. Serogroup-specific
disease incidence varies over time and by geographic location, thus
emphasizing the need for broadly-protective vaccines.
While children younger than four years of age, particularly those
under one year, remain at the greatest risk of IMD, there is a second
peak in disease incidence among adolescents and young adults, with
overall higher case-fatality rates among the latter age groups [2]. Social
behavioral patterns that significantly increase the risk of transmission
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of meningococcus are more commonly seen in adolescents and young
adults [1] and, as a corollary, these age groups exhibit the highest
carriage rates [4]. In the US, the Advisory Committee on
Immunization Practices (ACIP) recommends that adolescents receive
a primary dose of a quadrivalent meningococcal glycoconjugate
vaccine at 11 or 12 years of age, followed by a booster dose at 16 years
[5].
MenACWY-CRM (Menveo®, Novartis Vaccines, Siena, Italy) is a
meningococcal (serogroups A, C, W-135 and Y) oligosaccharide
CRM197 conjugate vaccine. Unlike the predecessor unconjugated
polysaccharide vaccines, glycoconjugate vaccines induce a T-cell
dependent antigen response, resulting in immunological memory and
longer lasting protection, and can reduce nasopharyngeal carriage,
thereby promoting herd immunity [6-8]. MenACWY-CRM is licensed
for use in subjects aged 2–55 years in more than 50 countries and,
following the recent approval by the US Food and Drug
Administration, it is the only quadrivalent meningococcal vaccine
approved for use in infants two months of age and older [9]. The
results of clinical trials in pediatric, adolescent and adult populations
demonstrate that MenACWY-CRM is highly immunogenic and well
tolerated across age groups [10-14].
In addition to the meningococcal glycoconjugate vaccine
recommendations, a single booster dose of a combined tetanus,
reduced diphtheria and acellular pertussis vaccine (Tdap) and three
doses of a human papillomavirus (HPV) recombinant vaccine are also
recommended for adolescent immunization.
An analysis of vaccination coverage in the US indicated that, while
the percentage of adolescents who received all recommended
vaccinations has increased in recent years, there remains a significant
percentage of adolescents (~58%) who do not receive all doses of
recommended vaccines [15]. Concomitant administration of the three
recommended vaccines can reduce the number of required visits to a
physician and increase vaccination coverage among adolescents;
however, the possibility of immunologic interference between co-
administered vaccines must be evaluated.
Previous evaluations of concomitant administration of MenACWY-
CRM with either Tdap alone [16] or with both Tdap and HPV
vaccines [17] in healthy adolescents demonstrate that MenACWY-
CRM is well tolerated and immunogenic against meningococcal
serogroups A, C, W-135, and Y following co-administration.
Moreover, concomitant administration of MenACWY-CRM did not
decrease protective antibody responses to diphtheria, tetanus, or HPV.
While the responses to the pertussis antigens did not meet the pre-
defined non-inferiority criteria in the referenced studies [16,17], these
findings are of unknown clinical significance, given the lack of an
established serocorrelate of protection against pertussis disease.
Neither of these studies included the comparison that is most relevant
to current US adolescent recommendations: namely, the comparison
of co-administration of MenACWY-CRM, Tdap, and HPV vaccines
versus co-administration of Tdap and HPV vaccines alone.
Here we report the results of an analysis of the immune responses
to a Tdap vaccine co-administered with MenACWY-CRM and a
quadrivalent HPV vaccine (HPV4), as compared to Tdap co-




This Phase IV, observer-blind, placebo-controlled, randomized
study was conducted across a total of 20 sites in the United States and
Italy between September, 2011 and December, 2012 (V59_40;
Clinicaltrials.gov identifier: NCT01424644). This clinical study was
conducted in accordance with the International Conference on
Harmonization (ICH) Guidelines for Good Clinical Practice,
applicable local regulations, and the Declaration of Helsinki. Prior to
subject enrollment, approval of the study protocol and protocol-
related documents was obtained from an Independent Ethics
Committee and written informed consent was obtained from all
subjects or, for subjects under 18 years of age, parents or legal
guardians.
There were two co-primary objectives for this study; one co-
primary objective of this study was to assess the non-inferiority of
immune responses to a Tdap vaccine when administered
concomitantly with the MenACWY-CRM and HPV4 vaccines, as
compared to the responses to Tdap when administered concomitantly
with a placebo and HPV4. The other co-primary objective of this study
was to assess the non-inferiority of immune responses to a HPV4
vaccine when administered concomitantly with MenACWY-CRM and
Tdap, as compared to responses to HPV4 when co-administered with
a placebo and Tdap; the results of the HPV4 immune responses are
not yet available and will be published separately. Secondary objectives
were to assess the immunogenicity of a single dose of MenACWY-
CRM when co-administered with Tdap and HPV4, and to evaluate the
safety and tolerability profile of the concomitantly administered
vaccines.
Subjects
A total of 801 healthy adolescents aged 10-18 years were
randomized (1:1) within each study center to receive one dose each of
MenACWY-CRM, Tdap and HPV4 vaccines (Men+Tdap+HPV
group) or one dose each of placebo, Tdap and HPV4 vaccines (Placebo
+Tdap+HPV) on Day 1 of the study. Subjects in both groups received
two additional doses of the HPV4 vaccine, administered at two and six
months after the first vaccination. Eligible study participants included
those who had given their written consent/assent and if applicable,
whose parents or legal guardians had given written informed consent
at the time of enrollment; and those who had received childhood
vaccinations against diphtheria, tetanus, and pertussis, as per local
regulations, but had not yet received any adolescent vaccines against
diphtheria, tetanus, or pertussis. Eligible female subjects were required
to have a negative urine pregnancy test and, if sexually active, to be
willing to adopt appropriate birth control measures during the study
period. Subjects were excluded if they had previous disease (confirmed
or suspected) caused by N. meningitidis; had household contact with
or intimate exposure to an individual with N. meningitidis infection
within 60 days prior to enrollment; had received any investigational or
licensed vaccines containing meningococcal antigens or a prior HPV
vaccination; had received or planned to receive any investigational or
licensed vaccine 30 days before or after the receipt of study vaccines;
had any serious acute, chronic or progressive disease, or an impaired
immune system; had a history of anaphylaxis/serious vaccine reactions
to any vaccine component; or had experienced significant acute
infection or fever (≥38°C) seven or three days, respectively, prior to
enrollment.
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Vaccines
The three vaccines used in this study were all licensed vaccines:
MenACWY-CRM (Menveo®, Novartis Vaccines, Siena, Italy), Tdap
(Boostrix®, GSK Biologicals, Rixensart, Belgium) and HPV4 (Gardasil®,
Merck & Co., Inc., Whitehouse Station, NJ). The MenACWY-CRM
vaccine, administered as a 0.5 mL dose, was prepared by
extemporaneous mixing, just before injection, of the lyophilized
MenA-CRM component with the liquid MenCWY-CRM component.
The placebo control was a sodium chloride solution (normal saline),
administered as a 0.5 mL dose by intramuscular (IM) injection in the
left deltoid. The Tdap and HPV4 vaccines were supplied as prefilled
syringes and prepared according to manufacturer’s instructions. The
MenACWY-CRM and Tdap vaccines were administered by IM
injection in the left or right deltoid, respectively; the HPV4 vaccine
was administered by IM injection in the right deltoid or the
anterolateral area of either thigh. All vaccines were administered by
trained, unblinded site personnel.
Immunogenicity analysis and endpoints
Blood samples (20 mL) for immunogenicity analyses were drawn
prior to the first vaccination (Visit 1; Day 1) and one month after the
first vaccination (Visit 2; Month 1) (Figure 1). Antibody responses to
the diphtheria, tetanus and pertussis antigens [pertussis toxin (PT),
filamentous hemagglutinin (FHA) and pertactin (PRN)] were
measured by enzyme-linked immunosorbent assay (ELISA).
Serological analyses against the Tdap antigens were performed by
Pharmaceutical Product Development, LLC (PPD; Wayne,
Pennsylvania). Anti-diphtheria and anti-tetanus antitoxin responses
were expressed as geometric mean concentrations (GMCs) and the
percentage of subjects with antibody levels ≥1.0 IU/mL, which are
correlates of protection. Anti-pertussis antibody responses were
expressed as GMCs and percentages of subjects with seroresponse for
each of the three antigens. Seroresponse for anti-PT, anti-FHA and
anti-PRN antibodies was defined as follows: for subjects with a pre-
vaccination antibody concentration below the lower limit of
quantitation (LLQ) (equal to 0.9, 2.9 and 3.0 IU/mL for PT, FHA and
PRN, respectively), a post-vaccination antibody concentration of at
least four times the LLQ; for subjects with a pre-vaccination antibody
concentration ≥LLQ, an antibody concentration of at least four times
the pre-vaccination concentration.
Immunogenicity of the MenACWY-CRM vaccine was assessed by
serum bactericidal assay using human complement (hSBA) against N.
meningitidis serogroups A, C, W-135 and Y and expressed as
percentage of subjects with seroresponse, percentage of subjects with
hSBA titers ≥8 [18] and hSBA geometric mean titers (GMTs).
Seroresponse was defined by an increase from pre-vaccination hSBA
titers <4 to post vaccination hSBA titers ≥8, or at least a four-fold
increase in hSBA titers for subjects with pre-vaccination titers ≥4. The
serological analyses for MenACWY-CRM were performed at Novartis
Vaccines, Clinical Serology Laboratory in Marburg, Germany.
Safety analysis
Subjects were observed for 30 minutes after vaccination for any
immediate reactions by blinded personnel. Subjects (or their parents/
guardians, when applicable) were provided with diary cards to record
solicited local and systemic reactions up to seven days after the Day 1
vaccination. Solicited local reactions, evaluated only for the
MenACWY-CRM and placebo injection sites, included pain at
injection site, erythema and induration. Solicited systemic reactions
included chills, nausea, malaise, myalgia, arthralgia, and headache,
rash and fever (≥38.0°C). The reactions were described by the subject
or parent/guardian as mild, moderate, or severe. Serious adverse
events (SAEs), medically attended adverse events (AEs) and other
unsolicited AEs (including new onset of chronic illness) were collected
from Day 1 to the end of the study and were judged by the investigator
as possibly related, probably related or not related to study
vaccination. All subjects who received at least one vaccination and
provided any safety data were considered evaluable for the safety
analyses.
Statistical analysis
Assuming 10% early terminated or non-eligible for analysis
subjects, approximately 800 subjects were planned to be enrolled in the
study (400 per vaccine group) in order to obtain 360 evaluable subjects
in each group. There were nine non-inferiority hypotheses underlying
the co-primary objectives (five Tdap and four HPV4) that were tested
in a stepwise approach, starting with the five Tdap non-inferiority
hypotheses. Due to the pre-specified ordering of the two co-primary
objectives, no alpha adjustment was required. The study sample size
afforded at least 98% power to reject each of the nine individual
hypotheses. Therefore, the overall power to reject all nine hypotheses
underlying the two co-primary objectives and conclude non-
inferiority of Tdap and HPV4 immune responses to MenACWY
+Tdap+HPV versus Placebo+Tdap+HPV was at least 83%
(0.989×100%).
The Tdap immunogenicity analyses were conducted on the Tdap
per protocol (PP) population [n=758 (95%)], which included subjects
who correctly received the relevant vaccinations, provided evaluable
serum samples on Day 1 and at one month-post vaccination and had
no major protocol deviations. Non-inferiority criteria for anti-
diphtheria and anti-tetanus antibodies were as follows: the lower limit
(LL) of the two-sided 95% confidence interval (CI) on the difference
between the groups [(Men+Tdap+HPV) minus (Placebo+Tdap
+HPV)] in the percentage of subjects with anti-tetanus and anti-
diphtheria toxin antibody levels ≥1.0 IU/mL must be greater than
−10% for each antigen. Non-inferiority criteria for pertussis antigens
were as follows: the LL of the two-sided 95% CI of the inter-group
ratio (Men+Tdap+HPV to Placebo+Tdap+HPV) of GMCs for each
pertussis antigen (PT, FHA, PRN) must be greater than 0.5. The two-
sided 95% CIs for group differences in diphtheria and tetanus response
rates were constructed using the method of Mee [19]. The group GMC
ratios for the anti-pertussis responses and their associated 2-sided 95%
CIs were computed by exponentiating (base10) the corresponding
vaccine group difference in least square means of the log10-
transformed concentrations and the associated 95% CI for the
difference obtained from an ANOVA model having factors for vaccine
group and study center. Data analyses were performed using SAS®
version 9.1.
The analyses of immune responses against N. meningitidis
serogroups A, C, W-135 and Y were performed on the MenACWY-
CRM PP population, which included all eligible subjects from the Men
+Tdap+HPV group (N=372) and a randomly selected subset of
subjects from the Placebo+Tdap+HPV group (N=100).
Safety analyses were primarily descriptive. Differences between the
vaccine groups in the frequency of solicited reactions reported after
the first vaccination were analyzed with Pearson’s chi-square test, or
Fisher’s Exact test, in the event of small expected cell sizes.
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Figure 1: Subject disposition flowchart.
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Results
Enrollment, study flow and demographics
Among 801 enrolled subjects, 793 (99%) were vaccinated on Day 1
and 741 (93%) completed the study. Reasons for premature
withdrawal included: lost to follow up (n=28), withdrawal of consent
(n=21), protocol deviations (n=7), administrative reasons (n=1), and
unable to classify (n=1). Additionally, two subjects from the Men
+Tdap+HPV group withdrew due to an adverse event (syncope, n=1;
pyrexia and headache, n=1), of which only one (with pyrexia and
headache) had received a study vaccination.
In the enrolled population, demographic parameters, such as age,
sex and race, were generally similar across the study groups (Table 1).
The average age of the subjects at study entry was 11.9 (±1.6) years and
the majority of the subjects were male (60%). Other baseline
characteristics such as mean weight, height and body mass index were
well balanced across the study groups.
 Men+Tdap+HPV Placebo+Tdap+HPV Total
 n=402 n=399 N=801
Age (Yrs) 11.9 ± 1.7 11.8 ± 1.5 11.9 ± 1.6
Sex    
Male 233 (58%) 244 (61%) 477 (60%)
Female 169 (42%) 155 (39%) 324 (40%)
Race    
Asian 5 (1%) 7 (2%) 12 (1%)
Black, Non-
Hispanic 39 (10%) 36 (9%) 75 (9%)
White, Non-
Hispanic 319 (79%) 310 (78%) 629 (79%)
Native American/
Alaskan 1 (<1%) 2 (<1%) 3 (<1%)
Pacific/Hawaii 0 2 (<1%) 2 (<1%)
Other 38 (9%) 42 (11%) 80 (10%)
Weight (kg 50.4 ± 15.7 50.6 ± 15.3 50.5 ± 15.5
(n=400) (n=398) (n=798)
Height (cm)
153.3±11.7 152.9±11.3 153.1 ± 11.5
(n=400) (n=398) (n=798)
Body Mass Index
21.1 ± 4.7 21.4 ± 5.0 21.2 ± 4.8
(n=400) (n=398) (n=798)
Table 1: Demographics of enrolled study participants
Immunogenicity
Tdap immunogenicity: One month post-Tdap vaccination, the
percentages of subjects with seroprotective anti-diphtheria or anti-
tetanus antibody concentrations (≥1.0 IU/mL) were high in both
vaccine groups. While there was a greater proportion of subjects with
seroprotective anti-diphtheria antibody concentrations in the Men
+Tdap+HPV group as compared to the Placebo+Tdap+HPV group,
(95% vs. 82%, respectively), the percentage of subjects with
seroprotective anti-tetanus antibody concentrations was similar
between groups (Men+Tdap+HPV: 99%; Placebo+Tdap+HPV: 98%)
(Table 2). The LL of the two-sided 95% CI for the difference in the
proportion of subjects with seroprotective anti-diphtheria and anti-
tetanus antibody concentrations between the study groups (Men
+Tdap+HPV minus Placebo+Tdap+HPV) at one month following
vaccination was 9% and -2%, respectively (Table 2), satisfying non-
inferiority criteria for the diphtheria and tetanus antigens.
Immune responses against the three pertussis antigens were similar
one month following co-administration of Tdap with MenACWY-
CRM and HPV or a placebo and HPV, with increases relative to
baseline in the GMCs of antibodies to pertussis toxin (PT),
filamentous hemagglutinin (FHA) and pertactin (PRN) of 9.2 to 11-
fold, 8.4 to 11 fold, and 16 to 19-fold, respectively, across the two
groups (Table 2). Non-inferiority of antibody responses to each of the
three pertussis antigens was also demonstrated at one month post-
vaccination when Tdap was co-administered with MenACWY-CRM
and HPV4 vaccines, as compared to when Tdap was administered with
a placebo and the HPV4 vaccine. Specifically, the LL of the two-sided
95% CI for the group ratio (Men+Tdap+HPV to Placebo+Tdap+HPV)
of the GMCs of antibodies to PT, FHA and PRN were all greater than
0.5 (PT, 0.89; FHA, 0.76; PRN, 0.72; Table 2).
Antigen Timing Men+Tdap+HPV Placebo+Tdap+HPV Vaccine Group Differences / Ratiosǂ
n % of subjects/GMC n % of subjects/GMC
% ≥ 1.0 IU/mL (95% CI) % ≥ 1.0 IU/mL (95% CI) Men+Tdap+HPV minus Placebo+Tdap
+HPV (95% CI)
Diphtheria
Baseline 375 5 (3, 8) 380 3 (2, 5) 2 (-1, 5)
Month 1 376 95 (93, 97) 382 82 (78, 86) 13 (9, 17)
Tetanus
Baseline 375 28 (24, 33) 380 28 (23, 32) 1 (-6, 7)
Month 1 376 99 (97, 100) 382 98 (97, 99) 0 (-2, 2)
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Pertussis antigen GMC (IU/ml#) (95% CI) GMC (95% CI) Ratio of Men+Tdap+HPV to Placebo
+Tdap+HPV (95% CI)
PT Baseline 375 4.77 (4.11, 5.53) 380 4.16 (3.59, 4.82) 1.15 (0.95, 1.39)
Month 1 376 44 (40, 48) 382 44 (40, 48) 1.01 (0.89, 1.14)
FHA Baseline 375 24 (21, 27) 380 21 (18, 23) 1.15 (0.98, 1.34)
Month 1 376 202 (187, 218) 382 240 (222, 259) 0.84 (0.76, 0.93)
Pertactin Baseline 375 20 (18, 23) 380 21 (18, 24) 0.99 (0.83, 1.18)
Month 1 376 330 (300, 363) 382 403 (367, 443) 0.82 (0.72, 0.93)
Table 2: Differences in Tdap antigen-specific immune responses between the Men+Tdap+HPV and Placebo+Tdap+HPV groups. Percentages
(95% confidence intervals) of subjects with seroprotective anti-diphtheria toxin and anti-tetanus toxin antibody levels and GMCs (95%
confidence intervals) of antibodies against pertussis antigens, at baseline and one month after Tdap vaccination. ǂBold values indicate that the
non-inferiority criteria were met. #GMCs are shown as ELISA units/ml
GMCs for anti-diphtheria and anti-tetanus antibodies are presented
in Figure 2. While the GMCs of anti-diphtheria antibodies were
similar in both vaccine groups prior to vaccination, there was a greater
increase in the GMCs one month after vaccination for the Men+Tdap
+HPV group (39-fold) as compared to the Placebo+Tdap+HPV group
(15-fold) (Figure 2A). GMCs for the anti-tetanus antibodies were
similar between groups both prior to vaccination and one month post-
vaccination, with increases of 12- and 15-fold in the Men+Tdap+HPV
group and Placebo+Tdap+HPV group, respectively (Figure 2A).
Additional analyses for antibody responses to the pertussis antigens
did not show any differences between the Men+Tdap+HPV and
Placebo+Tdap+HPV groups for the percentage of subjects in each
group achieving seroresponse for anti-PT antibodies (Men+Tdap
+HPV, 80%; Placebo+Tdap+HPV, 84%) and anti-PRN antibodies
(Men+Tdap+HPV, 88%; Placebo+Tdap+HPV, 92%) at one month
post-vaccination; whereas the percentage of subjects achieving
seroresponse for anti-FHA antibodies was lower in the Men+Tdap
+HPV group (72%) than the Placebo+Tdap+HPV group (81%)
(Figure 2B).
Figure 2: Tdap immunogenicity endpoints at one month post-Tdap-vaccination. (A) Geometric mean concentrations of anti-diphtheria and
anti-tetanus antibodies at baseline and one month post-vaccination, by group. (B) The percentage of subjects with seroresponse to the
pertussis antigens, pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN), by group.
MenACWY-CRM Immunogenicity: The majority of subjects in
both the Men+Tdap+HPV group and the Placebo+Tdap+HPV group
were seronegative (hSBA titers ˂4) at baseline for serogroups A (95%
vs. 96%, respectively), C (57% vs. 55%) and Y (62% vs. 72%); whereas,
the percentages of subjects who were seronegative for serogroup
W-135 prior to vaccination were overall lower (Men+Tdap+HPV
group, 34%; Placebo+Tdap+HPV group, 32%). Robust immune
responses against all four serogroups were evident at one month
following co-administration of a single dose of MenACWY-CRM with
the Tdap and HPV4 vaccines, with 77%, 84%, 95%, and 86% of
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subjects in the Men+Tdap+HPV group achieving hSBA titers ≥8
against meningococcal serogroups A, C, W-135 and Y, respectively
(Table 3). As expected, at one month post-vaccination, the percentages
of subjects in the Placebo+Tdap+HPV group with hSBA titers ≥8
against the four meningococcal serogroups were similar to baseline.
The percentages of subjects achieving seroresponse were high for
serogroups A, C and Y (75%, 69%, and 69%, respectively); whereas, the
percentage of subjects achieving seroresponse for serogroup W-135
was lower (49%)). A lower seroresponse to serogroup W-135 reflects
the high percentage of seropositive subjects (>65%) at baseline. In
contrast, following co-administration of the placebo with the Tdap
and HPV4 vaccines, only 1-5% of subjects showed seroresponse
against each individual serogroup.
In the Men+Tdap+HPV group, at one month post-vaccination the
GMT increases relative to baseline were higher against serogroups A
(16-fold), C (13-fold), and Y (12-fold), as compared to the increases
against serogroup W-135 (5-fold; Table 3); the lower relative increase
in GMTs against serogroup W-135 reflect the higher baseline hSBA
titers for this serogroup across both groups. As anticipated, there was
no change in GMTs from baseline to one month post-vaccination in
the Placebo+Tdap+HPV group.
Serogroup Men+Tdap+HPV Placebo+Tdap+HPV
n GMT / % of subjects n GMT / % of subjects
A 371 99
GMTs
Baseline 2.2 (2.1, 2.3) 2.1 (2.0, 2.3)
1 month post-vaccination 35 (29, 42) 2.1 (2.0, 2.3)
hSBA titer ≥8, % 77 (72, 81) 2 (0, 7)
Seroresponders, % 75 (70, 80) 1 (0, 5)
C 370 97
GMTs
Baseline 4.4 (4.0, 4.9) 3.9 (3.3, 4.6)
1 month post-vaccination 59 (48, 73) 3.9 (3.3, 4.7)
hSBA titer ≥8, % 84 (80, 88) 21 (13, 30)
Seroresponders, % 69 (64, 74) 2 (0, 7)
W-135 369 96
GMTs
Baseline 12 (10, 14) 12 (9.1, 16)
1 month post-vaccination 61 (53, 69) 12 (9.3, 17)
hSBA titer ≥8, % 95 (93, 97) 67 (56, 76)
Seroresponders, % 49 (44, 54) 5 (2, 12)
Y 369 97
GMT
Baseline 4.1 (3.7, 4.6) 3.5 (2.8, 4.3)
1 month post-vaccination 48 (40, 58) 3.5 (2.9, 4.3)
hSBA titer ≥8, % 86 (82, 89) 22 (14, 31)
Seroresponders, % 69 (64, 74) 3 (1, 9)
Table 3: Immunogenicity endpoints for meningococcal serogroups A, C, W-135 and Y responses. hSBA GMTs, percentage of subjects with hSBA
titer ≥8, and percentage of seroresponders against serogroups A, C, W-135, and Y, at baseline (GMTs only) and one month post vaccination, by
group.
Citation: Gasparini R, Johnston W, Conversano M, Garscadden A, Alexanderian D, et al. (2014) Immunogenicity and Safety of Combined
Tetanus, Reduced Diphtheria, Acellular Pertussis Vaccine when Co-Administered with Quadrivalent Meningococcal Conjugate and
Human Papillomavirus Vaccines in Healthy Adolescents. J Vaccines Vaccin 5: 231. doi:10.4172/2157-7560.1000231
Page 7 of 10
J Vaccines Vaccin
ISSN:2157-7560 JVV, an open access journal Volume 5 • Issue 3 • 1000231
Reactogenicity and Safety
Among 801 subjects in the enrolled population, 793 (99%) subjects
were exposed to the study vaccines, all of whom provided post-
vaccination safety data and were included in the safety analyses.
Excluding those individuals for whom data on solicited reactions were
not available, 774 (97%) subjects were included in reactogenicity
analyses; the percentages of subjects with any reported solicited
reaction within seven days of the first vaccination was 72% for the
Men+Tdap+HPV group and 64% for the Placebo+Tdap+HPV group.
Overall, the reported rates of both local and systemic solicited
reactions were higher in the Men+Tdap+HPV group than the Placebo
+Tdap+HPV group (local reactions: 54% vs. 43%; systemic reactions:
53% vs. 46%, respectively). Other solicited indicators of reactogenicity
(i.e., subjects stayed at home due to any reaction or used analgesics or
antipyretics) were reported in similar percentages of subjects for both
groups (Men+Tdap+HPV group, 23%; Placebo+Tdap+HPV group,
21%).
The most commonly reported solicited local reaction (at the
MenACWY-CRM or placebo injection site) within seven days
following vaccination was pain at the injection site, which was
reported by similar percentages of subjects in both groups (Men+Tdap
+HPV, 35% versus Placebo+Tdap+HPV, 41%), followed by erythema
(17% versus 7%; p<0.001) and induration (16% versus 10%; p=0.011)
(Figure 3A). Severe solicited local reactions were reported by up to 1%
of subjects across both vaccine groups.
The most commonly reported solicited systemic reaction within
seven days following vaccination was myalgia (26-30%), followed by
headache (25-29%), chills (13-15%) and malaise (11-15%), with no
statistically significant differences between groups in the frequencies of
each solicited systemic reaction (Figure 3B). Severe solicited systemic
reactions or fever were reported in no more than 1% or 2% of subjects,
respectively, in either vaccine group.
Figure 3: Summary of reported solicited reactions. Percentage of subjects reporting solicited local (A) or systemic (B) reactions within seven
days post-vaccination, by group.
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Unsolicited AEs were reported by similar percentages of subjects in
the Men+Tdap+HPV and Placebo+Tdap+HPV groups (51% versus
50%, respectively), with the most common unsolicited AEs being
injection site pain (Men+Tdap+HPV, 7% vs. Placebo+Tdap+HPV,
6%) and pharyngitis (Men+Tdap+HPV, 6% vs. Placebo+Tdap+HPV,
5%). The frequencies of diagnoses of new onset chronic disease were
similar between the Men+Tdap+HPV group (6%) and the Placebo
+Tdap+HPV group (7%). The most frequently reported chronic
conditions were seasonal allergies and minor dermatology conditions,
such as acne and atopic dermatitis, consistent with expected patterns
for this age group.
A total of seven subjects reported nine SAEs during the entire study
period, with hematuria, abdominal adhesion, small intestinal
obstruction, aggression, hypothyroidism and type 1 diabetes mellitus
reported by subjects in the Men+Tdap+HPV group and peritonsillar
abscess, accidental overdose and affective disorder reported in the
Placebo+Tdap+HPV group. With the exception of the subject with
affective disorder, all subjects recovered from the SAEs (or recovered
from acute manifestations of the SAEs, in the case of the subject with
hypothyroidism and type 1 diabetes mellitus), and none of the SAEs
were considered to be related to the study vaccine. There were no
deaths reported in this study.
Discussion
Adolescents are at increased risk of vaccine-preventable diseases,
due to waning protective immunity conferred by childhood
vaccination against pertussis, as well as social behaviors that increase
their exposure to meningococcus, Bordetella pertussis, and HPV [20].
While immunization compliance among adolescents is not very well
monitored in most countries, estimates of vaccine coverage in this age
group in the US indicate that compliance is lower than that observed
for vaccinations recommended for infants and toddlers [15]. Lower
immunization compliance among adolescents is attributed, at least in
part, to infrequent healthcare visits and the resulting missed
opportunity for vaccination [20,21]. Concomitant administration of
recommended vaccines can increase compliance in adolescents
substantially, provided that immunologic interference between
vaccines does not occur. In particular, the results of an analysis on
adolescent vaccination coverage in the US indicate that simultaneous
administration of indicated vaccines could increase coverage for Tdap
and MenACWY vaccines from ≥ 54% to >80%, and for the first dose
of a HPV vaccine from 44% to 74% [15].
In the present study, we demonstrate that following co-
administration of the MenACWY-CRM, Tdap, and HPV4 vaccines,
immune responses to all five Tdap antigens were non-inferior to those
following co-administration of a placebo with the Tdap and HPV4
vaccines. In contrast to previous studies examining co-administration
of MenACWY-CRM and Tdap [16,17], non-inferiority criteria were
met for all three pertussis antigens tested.
In the earlier studies, the direct comparators for Tdap immune
responses were either Tdap alone [17] or Tdap administered with a
placebo [16]. In contrast, the direct comparator group of the present
study received a placebo with both Tdap and HPV4. The differences in
the responses to the pertussis antigens between the studies could be
attributed to the different control groups or to other factors, such as
geographic location or variability in the immune assays used to assess
these responses.
In this study, we found that antibody concentrations to the
diphtheria toxoid one month after vaccination were substantially
higher in the Men+Tdap+HPV group than the Placebo+Tdap+HPV
group. Similar augmentation of anti-diphtheria responses in
adolescents following co-administration of MenACWY-CRM with
Tdap has been reported previously [16,17] and is likely attributed to
the use of CRM197, a nontoxic mutant of diphtheria toxin, as the
carrier protein in MenACWY-CRM; however, the clinical relevance of
this augmented response is not known.
We also found that co-administration of MenACWY-CRM with
Tdap and HPV4 vaccines induced robust immune responses to N.
meningitidis serogroups A, C, W-135, and Y; the high percentages of
subjects with hSBA titers ≥8 against the four serogroups (77-95%)
were similar to those observed previously following co-administration
of MenACWY-CRM with Tdap and HPV4 vaccines [17] or
MenACWY-CRM with Tdap [16] in adolescents. In addition, the
responses against serogroups A, C, W-135, Y following concomitant
administration of MenACWY-CRM, Tdap and HPV4 vaccines
observed in this study were similar to those observed in adolescents
following administration of MenACWY-CRM alone [12].
The relatively low overall seroresponse rate to serogroup W-135 in
the Men+Tdap+HPV group is likely attributable to the high
percentage of subjects (66%) with hSBA titers ≥4 against this
serogroup prior to vaccination. The high percentage of baseline
serogroup W-135 seropositivity observed in this study has been
described elsewhere [12,17], and could be attributed to cross-reactive
antibodies, or could potentially reflect the high rates of asymptomatic
nasopharyngeal carriage observed among adolescents and young
adults [4].
In the present study, the safety profile of the MenACWY-CRM
vaccine concomitantly administered with Tdap and HPV4 vaccines,
including the rates of any AEs, possibly related AEs, medically-
attended AEs and new onset of chronic disease, was similar to that of
the placebo, co-administered with the Tdap and HPV4 vaccines. The
pattern of individual unsolicited AEs reported was typical in
adolescents and similar in both study groups.
Reports of any solicited reaction were overall higher in the Men
+Tdap+HPV group as compared to the Placebo+Tdap+HPV group;
however, among all reported reactions, statistically significant
differences between groups were only observed for the rates of
erythema and induration, which were assessed at the injection site for
MenACWY-CRM and placebo only. For all local and systemic
reactions, most were mild to moderate in nature, with ≤ 1% of subjects
reporting severe solicited reactions. Overall, the frequencies of these
reactions were similar to those observed previously in adolescents who
had received MenACWY-CRM either alone [12] or co-administered
with Tdap and HPV4 vaccines [17].
Collectively, the results of this study demonstrate that MenACWY-
CRM co-administered with Tdap and HPV4 vaccines does not
interfere with immune responses against the tetanus, diphtheria, and
pertussis antigens in Tdap. Moreover, the results demonstrate that
MenACWY-CRM co-administered with Tdap and HPV4 vaccines
elicits highly immunogenic responses against meningococcal
serogroups A, C, W-135 and Y, and has an acceptable reactogenicity
profile. These studies support the concomitant use of MenACWY-
CRM with other recommended adolescent vaccines, thereby
increasing the likelihood of vaccine compliance among this age group.
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